PDT FOR CHOLANGIOCARCINOMA
SURVIVAL BENEFIT FROM PALLIATIVE BILE DUCT TREATMENT

Cholangiocarcinoma — cancer of the bile ducts — is diagnosed at an unresectable stage in 70–80% of patients. Surgical resection is the only curative option, but most patients present with locally advanced or metastatic disease that precludes surgery. The standard palliative approach has been biliary drainage (stenting) to relieve jaundice, combined with systemic chemotherapy. PDT adds a meaningful survival layer that chemotherapy alone cannot match in the local biliary disease.

“Biliary stenting keeps the bile flowing. PDT destroys the tumour causing the obstruction. Together they do more than either alone — and the survival data supports this more clearly in cholangiocarcinoma than in almost any other PDT indication.”

• Why Most Cholangiocarcinoma Is Unresectable

  Hilar cholangiocarcinoma (Klatskin tumour) — the most common subtype — grows at the confluence of the left and right hepatic ducts, often infiltrating both biliary and vascular structures by the time of diagnosis. The proximity to the portal vein and hepatic artery, combined with bilaterally involved ducts, makes surgical resection impossible in most cases. Intrahepatic cholangiocarcinoma may be resectable if limited, but also frequently presents with multifocal or vascular involvement.

• Why Standard Stenting Alone Is Insufficient

  Biliary stents drain bile past the obstruction — relieving jaundice and preventing cholangitis. But they do nothing to control tumour growth. Stent ingrowth by tumour causes progressive re-obstruction, requiring repeat procedures. Tumour continues growing, eventually causing liver failure. PDT adds direct tumour cytotoxicity and potentially reduces the rate of stent ingrowth — extending the functional duration of drainage and overall survival.

Published randomised controlled trial data comparing PDT + biliary stenting to biliary stenting alone in unresectable cholangiocarcinoma.

Delivering PDT to the bile ducts requires specialised endoscopic or percutaneous access — more technically demanding than oesophageal or bronchoscopic PDT, but performed routinely at experienced hepatobiliary centres.

• Photofrin Injection (Same Protocol as Oesophageal PDT)

  Photofrin 2 mg/kg IV, 40–50 hours before light delivery. The same drug, same dose, same drug-to-light interval as oesophageal PDT. The photosensitiser accumulates in the cholangiocarcinoma cells lining the bile duct — the drug itself does not differ; only the light delivery access changes.

• ERCP-Based Biliary Light Delivery

  Under sedation, ERCP (endoscopic retrograde cholangiopancreatography) is performed. A thin optical fibre (cylindrical diffuser, typically 1–3 cm active length) is advanced through the endoscope into the bile duct over a guidewire and positioned within the tumour under fluoroscopic guidance. Red laser light at 630 nm is delivered at 180–200 J/cm for 500–1,000 seconds.

• Percutaneous Transhepatic Cholangioscopy (PTC) Access

  For hilar cholangiocarcinomas where bilateral duct access is required or where ERCP access is technically limited, percutaneous transhepatic cholangioscopy provides direct biliary access. A catheter introduced through the skin and liver into the bile duct delivers the optical fibre to the tumour. This approach allows treatment of both right and left hepatic duct involvement.

• Biliary Stent Placement After PDT

  Following light delivery, biliary stents (typically plastic or covered metal stents) are placed to maintain drainage through the treated area during the tumour necrosis and sloughing phase. The stents also prevent acute obstruction from necrotic debris. Stent exchange is planned at 3-month intervals — at which point response endoscopy assesses tumour and repeat PDT is planned if appropriate.

Selection criteria that determine PDT candidacy in unresectable cholangiocarcinoma.

Most patients with unresectable cholangiocarcinoma receive systemic chemotherapy (gemcitabine + cisplatin is the standard first-line regimen). The combination of biliary PDT with chemotherapy is increasingly the standard approach at experienced centres.

• Rationale for Combination

  PDT addresses the local biliary disease — the dominant cause of morbidity and early mortality in cholangiocarcinoma. Chemotherapy addresses systemic micrometastatic disease. They act on different disease compartments with non-overlapping mechanisms. Several retrospective series and prospective studies combining Photofrin PDT with gemcitabine-based chemotherapy show favourable outcomes, with median OS exceeding 24 months in selected patients.

• Typical Combined Approach

  Biliary PDT (1–3 sessions every 3 months as needed for disease control) combined with systemic gemcitabine + cisplatin (or gemcitabine + oxaliplatin) as the chemotherapy backbone. More recently, immunotherapy combinations (durvalumab + chemotherapy) represent the new first-line standard — the interaction between PDT immune activation and checkpoint inhibition is an active research area.

Related PDT topics and resources.

Frequently Asked Questions

Common questions about PDT for cholangiocarcinoma.